Wegovy on Medicare 2026: $50 Coverage Under the GLP-1 Bridge

Last updated: May 11, 2026 · Reading time: 10 minutes

Wegovy is one of three GLP-1 medications eligible Medicare beneficiaries can get for $50 a month starting July 1, 2026, under the Medicare GLP-1 Bridge. It’s the only one of the three that’s both an injection and a pill, and the only one with a separate FDA-approved indication for reducing the risk of heart attack and stroke. That second indication creates a coverage wrinkle that catches a lot of people off guard.

This page covers everything Medicare beneficiaries need to know about Wegovy specifically: which doses and formulations qualify, how the Bridge handles Wegovy compared to standard Part D, what to expect at the pharmacy counter, and how Wegovy compares to Zepbound and Foundayo for someone choosing among the three. For the program rules in general, see our complete guide to the Medicare GLP-1 Bridge and the full eligibility breakdown.

Wegovy on Medicare: The 60-Second Summary

What Wegovy is: A GLP-1 medication (active ingredient: semaglutide) made by Novo Nordisk. Available as a weekly injection and a daily pill.

Bridge coverage: All formulations and all doses of Wegovy are covered under the Medicare GLP-1 Bridge for eligible beneficiaries with the obesity indication.

What it costs under the Bridge: $50 per month, regardless of dose. This applies to both the injection pen and the oral pill.

Doses covered: Injection at 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg. Oral pill at 1.5 mg, 4 mg, 9 mg, and 25 mg.

The coverage wrinkle: If your Wegovy is prescribed for cardiovascular risk reduction (a separate FDA indication), it’s covered under standard Part D, not the Bridge. The drug is the same. The price you pay is not.

Where to fill it: Any pharmacy that accepts Part D. The pharmacist bills the CMS central processor using BIN 028918 and PCN MEDDGLP1BR.

[LEAD FORM PLACEHOLDER: “See if you qualify for $50 Wegovy on Medicare”]

What Wegovy Actually Is

Wegovy contains semaglutide, the same active ingredient as Ozempic. The difference is the dose and the FDA-approved use. Ozempic is FDA-approved for Type 2 diabetes at lower doses. Wegovy is approved for chronic weight management at higher doses, and for cardiovascular risk reduction in adults with established heart disease and obesity or overweight.

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a hormone your body produces after eating. The hormone signals fullness, slows stomach emptying, and reduces appetite. People taking Wegovy report feeling full sooner and staying full longer, which translates into eating less without conscious effort.

In the STEP-1 clinical trial, adults taking Wegovy 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% with placebo. For someone weighing 220 pounds at the start, that’s roughly 33 pounds.

Novo Nordisk launched the Wegovy oral pill in early 2026. The pill comes with one significant restriction: it has to be taken on an empty stomach, with no more than four ounces of water, and you have to wait at least 30 minutes before eating, drinking anything else, or taking other medications. That restriction is the main reason Eli Lilly’s competing Foundayo pill has been positioned as easier to take.

Wegovy Doses and Formulations Covered Under the Bridge

According to Novo Nordisk’s announcement of Medicare access, all formulations and all doses of Wegovy are covered under the Bridge for eligible beneficiaries. That’s unusual; the program restricts Zepbound to a single formulation (KwikPen only). Wegovy faces no such restriction.

Wegovy injection doses covered under the Bridge:

  • 0.25 mg (starting dose)
  • 0.5 mg
  • 1.0 mg
  • 1.7 mg
  • 2.4 mg (maintenance dose for chronic weight management)
  • 7.2 mg (higher-dose formulation introduced 2025)

Wegovy oral pill doses covered:

  • 1.5 mg
  • 4 mg
  • 9 mg
  • 25 mg

The pill and injection deliver the same active ingredient. Choice between them comes down to your preference, your tolerance for daily versus weekly dosing, and your willingness to follow the empty-stomach-and-water restrictions on the pill. The $50 monthly Bridge price is the same regardless of which you choose.

According to Lilly competitor analysis published by SingleCare, the injection produces somewhat greater weight loss than the pill at maximum doses (around 15-17% body weight reduction for the injection versus 12-14% for the pill in trials), but real-world results vary substantially based on adherence and dose titration.

The Cardiovascular Indication: A Coverage Wrinkle

This is the part most coverage of the Bridge skips, and it’s the most likely to confuse someone trying to figure out what they’ll pay.

Wegovy has two FDA-approved uses on Medicare. The first is chronic weight management. The second is reducing the risk of major cardiovascular events (cardiovascular death, heart attack, and stroke) in adults with established cardiovascular disease and either obesity or overweight. The cardiovascular indication was approved by the FDA in March 2024 based on the SELECT trial, which showed a 20% reduction in major cardiac events and a 28% reduction in heart attacks in patients on Wegovy 2.4 mg versus placebo.

Here’s the wrinkle. The cardiovascular indication was already covered by Medicare Part D before the Bridge existed. CMS issued guidance in 2024 that Part D plans could add Wegovy to their formularies for the CV indication, since it has a medically accepted use that isn’t specifically excluded from Medicare coverage. Roughly 3.6 million Medicare beneficiaries fit the CV indication criteria, according to KFF analysis.

So if you have cardiovascular disease and obesity, your Wegovy could theoretically be covered under either pathway: Part D (for the CV indication) or the Bridge (for the obesity indication). The two pathways have different prices.

  • Part D for the CV indication: You pay your plan’s copay or coinsurance, which varies widely. Some plans have generous coverage; others put Wegovy on a high specialty tier with substantial cost-sharing.
  • Bridge for the obesity indication: Flat $50 per month, but doesn’t count toward your Part D deductible or out-of-pocket cap.

Which is better depends on your specific Part D plan and your total drug spending. If your plan covers Wegovy generously for the CV indication and the copay is under $50, Part D wins. If your plan puts it on a high tier with a $200+ copay, the Bridge wins. If you’re a high drug spender approaching your annual out-of-pocket cap, Part D coverage might be more valuable than it looks because those costs count toward your $2,100 cap, while Bridge costs don’t.

Talk to your prescriber about which indication appears on your prior authorization. The indication on the prior auth is what determines which pathway you’re routed through.

Wegovy vs. Zepbound vs. Foundayo: How They Compare

All three drugs are covered under the Bridge for $50 a month, so cost isn’t the differentiator. The choice comes down to clinical and practical factors.

Wegovy is the only one of the three with an FDA-approved cardiovascular indication, which matters if you have established heart disease. Available as a weekly injection or a once-daily pill. The injection is a single-use pen; the pill comes with the empty-stomach restriction described above.

Zepbound (tirzepatide, made by Eli Lilly) is the only dual GIP/GLP-1 receptor agonist of the three, which means it activates two different receptors instead of one. Head-to-head against Wegovy injection in the SURMOUNT-5 trial, Zepbound 15 mg produced an average 20.2% weight loss versus 13.7% for Wegovy 2.4 mg over 72 weeks. Available only as a weekly injection under the Bridge, in KwikPen formulation only.

Foundayo (orforglipron, made by Eli Lilly) is a daily pill with no food or water restrictions. Approved by the FDA in April 2026, so it’s the newest of the three. Produced an average 12.4% weight loss at the highest dose in the ATTAIN-1 trial.

A simplified way to think about it: Zepbound produces the most weight loss on average and is injection-only. Foundayo is the easiest to take (daily pill, no restrictions) but produces less weight loss. Wegovy sits in the middle, with the unique advantage of the CV indication.

Your prescriber will factor in your tolerance for injections, your medical history, your willingness to follow the Wegovy pill’s restrictions, and whether the CV indication applies. For a deeper comparison, see Wegovy vs. Zepbound vs. Foundayo: which to ask your doctor about (coming soon).

How to Get Wegovy Under the Bridge

The mechanics are the same as for any Bridge medication, with one Wegovy-specific consideration: which indication appears on your prior authorization.

  1. Confirm you have Medicare Part D. Standalone PDP or Medicare Advantage with drug coverage.
  2. Talk to your doctor about Wegovy specifically. If you have heart disease and obesity, ask whether the obesity indication (Bridge, $50) or the CV indication (Part D, varies) makes more financial sense given your plan.
  3. Your doctor submits a prior authorization to the CMS central processor, not your Part D plan. The prescription specifies the dose and formulation (injection or pill).
  4. Once approved, fill at any pharmacy. Pharmacist bills the central processor using BIN 028918 and PCN MEDDGLP1BR.
  5. Pay $50 at the counter.

If your pharmacy has trouble processing the claim in the first weeks after July 1 (likely, since the Bridge uses a different billing pathway than standard Part D), Novo Nordisk operates a NovoCare hotline at 1-888-809-3942 that can help with coverage questions.

Wegovy Side Effects and Considerations

Wegovy carries a boxed warning for thyroid C-cell tumors based on rat studies. People with a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, should not use Wegovy.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and headache. These tend to be worst during dose escalation and improve over time. Most patients tolerate them with dose adjustments.

Less common but serious side effects include pancreatitis, gallbladder problems, kidney problems (usually from dehydration due to vomiting or diarrhea), and severe allergic reactions. Patients on insulin or insulin secretagogues for diabetes can develop low blood sugar.

This page is not medical advice. Discuss your full medical history, current medications, and any contraindications with your prescriber before starting Wegovy.

Frequently Asked Questions

Is Wegovy the same as Ozempic?

Same active ingredient (semaglutide), different doses, different FDA-approved uses. Ozempic is approved for Type 2 diabetes. Wegovy is approved for chronic weight management and cardiovascular risk reduction. Under Medicare, Ozempic is covered through standard Part D for diabetes; Wegovy is covered through the Bridge for obesity or through Part D for the CV indication.

Can I switch from the injection to the pill (or vice versa)?

Yes, with a new prescription and a new prior authorization. The Bridge covers both formulations.

Will my Part D plan affect my Wegovy Bridge access?

No. The Bridge operates outside Part D. Your plan’s Wegovy formulary placement doesn’t affect Bridge access. The Bridge is the same $50 regardless of which Part D plan you have.

What if I’m already paying out of pocket for Wegovy and my BMI has dropped below the threshold?

Eligibility is assessed at the time you started Wegovy, not at the time of the prior authorization. Your prescriber attests to your starting BMI. You qualify.

Does Wegovy interact with other medications?

It can. Wegovy slows gastric emptying, which affects absorption of oral medications. Patients on oral hormonal contraceptives are advised to use a non-oral or barrier method for four weeks after starting Wegovy and after each dose escalation. Discuss all your current medications with your prescriber.

What happens to Wegovy coverage when the Bridge ends in 2027?

Unknown. The Bridge expires December 31, 2027, with a planned transition to the BALANCE Model in 2028, which would shift coverage back into Part D. Whether Wegovy stays at $50 or returns to a higher Part D copay structure isn’t determined yet.

Sources and References

This guide is for informational purposes only and is not medical advice. Wegovy carries serious safety considerations including a boxed warning. Discuss your full medical history and current medications with a licensed healthcare provider before starting any GLP-1 therapy. Weight Loss RX Guide is not affiliated with CMS, Medicare, or Novo Nordisk. We may receive compensation when readers connect with services through links on this site; see our affiliate disclosure for details.

Subscribe
Subscribe